Armistice Capital LLC Has $29.02 Million Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR

Key Points

• Armistice Capital LLC sold 222,000 shares of Immunocore Holdings, reducing its holdings by 18.5% to approximately 978,000 shares, valued at about $29 million.
• Immunocore's stock has seen a 30% increase in revenue year-over-year, reporting $130.65 million for the latest quarter, exceeding analyst estimates.
• Analysts have mixed ratings on Immunocore, with seven "buy" ratings, three "hold" ratings, and one "sell" rating, indicating a general positive outlook despite recent rating adjustments.

Armistice Capital LLC lowered its position in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) by 18.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 978,000 shares of the company's stock after selling 222,000 shares during the period. Armistice Capital LLC owned 1.95% of Immunocore worth $29,017,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Barclays PLC increased its stake in shares of Immunocore by 2,044.0% during the fourth quarter. Barclays PLC now owns 20,625 shares of the company's stock worth $608,000 after purchasing an additional 19,663 shares during the period. Oppenheimer Asset Management Inc. bought a new position in shares of Immunocore during the first quarter worth approximately $225,000. GAMMA Investing LLC increased its stake in shares of Immunocore by 3,318.1% during the first quarter. GAMMA Investing LLC now owns 19,107 shares of the company's stock worth $5,670,000 after purchasing an additional 18,548 shares during the period. T. Rowe Price Investment Management Inc. increased its holdings in shares of Immunocore by 5.2% during the first quarter. T. Rowe Price Investment Management Inc. now owns 7,051,818 shares of the company's stock worth $209,228,000 after purchasing an additional 351,610 shares during the period. Finally, Point72 Asset Management L.P. bought a new position in shares of Immunocore during the fourth quarter worth approximately $11,897,000. Institutional investors own 84.50% of the company's stock.

Immunocore Stock Up 9.3%

NASDAQ:IMCR traded up $3.01 during mid-day trading on Wednesday, reaching $35.27. The stock had a trading volume of 516,959 shares, compared to its average volume of 295,853. The stock has a 50-day simple moving average of $33.37 and a two-hundred day simple moving average of $31.42. The company has a debt-to-equity ratio of 1.01, a quick ratio of 5.86 and a current ratio of 5.89. Immunocore Holdings PLC Sponsored ADR has a 12 month low of $23.15 and a 12 month high of $39.33.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.01. The business had revenue of $130.65 million for the quarter, compared to analysts' expectations of $122.96 million. Immunocore had a negative net margin of 5.70% and a negative return on equity of 5.40%. The firm's quarterly revenue was up 30.0% compared to the same quarter last year. During the same period last year, the firm posted ($0.23) earnings per share. On average, research analysts anticipate that Immunocore Holdings PLC Sponsored ADR will post -0.94 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Immunocore in a report on Tuesday, May 27th. They set a "buy" rating and a $65.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $100.00 target price on shares of Immunocore in a report on Monday, June 2nd. Wall Street Zen cut shares of Immunocore from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Oppenheimer raised their target price on shares of Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Finally, Jefferies Financial Group assumed coverage on shares of Immunocore in a report on Monday, August 25th. They set a "buy" rating and a $48.00 target price on the stock. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Immunocore currently has an average rating of "Moderate Buy" and an average price target of $56.89.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.